Month: June 2025

In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with complete preservation of lean mass, outperforming the group given semaglutide alone Icovamenib promoted healthy myotube morphology and diminished drug-induced atrophy in ex vivo 3D-engineered human myotube cultures In severely insulin-deficient patients from the Phase II COVALENT-111 trial, icovamenib achieved a 1.0% placebo-adjusted mean HbA1c reduction and a 55% increase in C-peptide at Week 26, three weeks after last doseSAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (Biomea or Biomea Fusion) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the presentation of new preclinical and clinical data for...

TORONTO, June 23, 2025 (GLOBE NEWSWIRE) — Churchill Resources Inc. (“Churchill” or the “Company”) (TSXV: CRI) is pleased to announce that due-diligence sampling on its Black Raven property returned silver assays of up to 395 g/t silver from grab samples, confirming that high-grade Ag, Sb, and Au are present at several prospects. Five grab samples returned silver assays over 150 g/t (4.69 opt), along with high-grade gold, lead and zinc, emphasizing the polymetallic metal assemblage of critical minerals present in the Black Raven vein system, per the summary table and figure below.Sample #   300   304   305   315   321Silver grade (g/t)   153   329   321   251   395Gold grade (g/t)   3.07   7.70   7.79   5.09   2.16Lead grade (%)   3.10   6.47   5.80   8.83   7.34Zinc grade (%)   2.85   4.97   >5.0   >5.0   >5.0Copper...

From OEM Pilots to Production Line: Scaling Solar Power in Commercial Transport West Palm Beach, FL, June 23, 2025 (GLOBE NEWSWIRE) — The solar technology company Sono Group N.V. (OTCQB: SEVCF) (hereafter referred to as “Sono Group” or “Sono”, parent company to Sono Motors GmbH or “Sono Motors”) today issued a shareholder update from George O’Leary, Managing Director and Chief Executive Officer. Dear Shareholders, The past six months have been about one thing: getting it done. After years of engineering, piloting, and positioning, we’re now watching our solar technology move into real commercial use — with real commercial vehicles, real fleets, and real revenue behind it. This progress didn’t happen overnight. It’s the result of over a year of hands-on engineering, close collaboration with OEMs, rigorous testing, and showing,...

16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients Robust central nervous system (CNS) activity; 41% (7/17) confirmed complete response (CR) and 53% confirmed overall response (ORR) in CNS evaluable disease patients by BICR in overall cohort Enrollment of first patient in a randomized, global pivotal Phase 3 (ALPACCA) study in first-line PACC patients expected in the second half of 2025 ArriVent to host virtual webinar today at 8 am ET NEWTOWN SQUARE, Pa., June 23, 2025 (GLOBE NEWSWIRE) — ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced encouraging additional follow up proof-of-concept data...

MELBOURNE, Australia and INDIANAPOLIS, June 23, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved a label expansion for Illuccix® (kit for the preparation of gallium Ga-68 gozetotide, for injection) to include patient selection for radioligand therapy (RLT) in the pre-taxane setting. The update applies to Illuccix’s third indication, for selection of patients who are indicated for PSMA1-directed therapy as described in the Prescribing Information of the therapeutic products. The label expansion follows the FDA’s approval of an expanded label for Pluvicto®2 (lutetium Lu177 vipivotide tetraxetan) for use in metastatic castration-resistant prostate cancer (mCRPC) patients after treatment...

TORONTO, June 23, 2025 (GLOBE NEWSWIRE) — Flow Capital Corp. (TSXV:FW) (“Flow Capital” or the “Company”) is pleased to announce a second follow-on investment of $1.5M in portfolio company, GetTattle Inc. (dba “Tattle”), a global Customer Experience Improvement (“CXI”) software-as-a-service (“SaaS”) platform focused primarily on the restaurant and hospitality sector. This follow-on round brings Flow Capital’s total investment in Tattle to US$5.5 million, and reaffirms the Company’s strong conviction in Tattle’s team, market opportunity, and long-term trajectory. The additional capital infusion will support Tattle’s continued growth driven by the launch of its AI Coach features, and further expand its presence within core enterprise verticals. Alongside the recent financing, Tattle announced the appointment of Kevin Quinn to its...

Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash   Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business   Simplifies Operating Structure and Enables Achievement of Adjusted EBITDA Break-Even    Cash & Cash Equivalents of At Least $550 Million Expected at Close to Fuel Inorganic Growth Strategy and Drive Long-Term Value Creation SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) — Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced the strategic sale of SomaLogic to Illumina, Inc. (NASDAQ: ILMN) (“Illumina”), including SomaScan® Assay Services, Authorized Sites and KREX™ for an upfront payment of $350 million in cash at closing and up to $75 million in...

New Hire Follows Multiple Customer MOU Announcements in May and June, Ensuring USAR will Remain on Track to Deliver Neo Magnets and Support Customers in 2026 STILLWATER, Okla., June 23, 2025 (GLOBE NEWSWIRE) — USA Rare Earth, Inc. (Nasdaq: USAR) (USAR or the Company), today announced the appointment of Ron Fogarty as Vice President of Sales. Mr. Fogarty will lead global sales efforts in support of the Company’s sintered neodymium (neo) magnet production facility in Stillwater, Oklahoma. Mr. Fogarty has over 35 years of sales, business development and organizational enhancement experience, and most recently served as Vice President of Sales for ABB, a global technology leader in electrification and automation. Fogarty will bring his expertise in driving sustainable growth, streamlining go-to-market operations, and aligning teams...

– Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 Receptor (IL-4R) – WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1a/1b program for ATI-052, the Company’s potential best-in-class investigational bispecific anti-TSLP/IL-4R antibody. The program will consist of a Phase 1a single and multiple ascending dose (SAD/MAD) portion in healthy volunteers, followed by an expected Phase 1b proof of concept portion. “This is an important milestone in the development of ATI-052, our uniquely potent bispecific anti-TSLP/IL-4R antibody,...